Matthew D. Disney is affiliated with the Scripps Research Institute.[1]He is a member of Department of Chemistry.[1]
He earned his B.S. at the University of Maryland and both his M.S. and Ph.D. at the University of Rochester, before completing a postdoctoral fellowship at the Massachusetts Institute of Technology and the Swiss Federal Institute of Technology in Zurich, Switzerland.[2]Dr. Disney is a full professor in the bi-coastal Department of Chemistry at The Scripps Research Institute with laboratories on the Florida campus of TSRI.[2]His group has developed broad approaches to the directed use of RNA genome sequence to inform the development of lead small-molecule medicines for multiple conditions with unprecedented potency and selectivity.[3]His research has now been published in the Journal of the American Chemical Society.[4]His research focuses on RNA-based drug discovery.[5]His work has also garnered many awards, including the NIH Director's Pioneer Award, the Tetrahedron Young Investigator Award, the James Watson Investigator Award and others.[6]
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Scripps Research Institute
7
452
76
Imagine trying to throw a bullseye when the dartboard lies buried within a crumpled box. That's the challenge faced by scientists working to make new medicines for some 'undruggable' diseases, including a type of metastatic breast cancer. The new RNA drug-discovery tool, described in Monday's issue of the Proceedings of the National Academy of Sciences, addresses these and other challenges to enable both the rapid discovery and optimization of RNA-targeting compounds, says Chemist Matthew Disney, Ph.D., of Scripps Research, Florida.[9]
12/15/2020
Co-lead researcher Matthew Disney says the RNA-binding compounds actively break the clutch of the virus and could curb the spread of the virus. “Our concept was to develop lead medicines capable of breaking COVID-19's clutch,” says Disney, a chemist at the Scripps Research Institute. Disney asserts that while the findings are promising, there’s still plenty of work and research to be done before the RNA-targeting compounds can be approved as a treatment for COVID-19. Targeting “druggable elements in RNA”[11]
10/21/2020
Matthew Disney, PhD, of Scripps Research in Jupiter, Florida, has spent over a decade developing tools to make RNA a druggable target for curing diseases. His lab's latest target is COVID-19, which is caused by a RNA virus. "This is a proof-of-concept study," Disney says. Using a database of RNA-binding chemical entities developed by Disney, they found 26 candidate compounds.[10]
09/30/2020